Sheng Y, Guo Y, Zhao B, Sun M, Dong Y, Yin Y
Commun Biol. 2025; 8(1):425.
PMID: 40082595
PMC: 11906777.
DOI: 10.1038/s42003-025-07854-x.
Yu T, Biswas A, Dube N, Okafor C
ACS Bio Med Chem Au. 2025; 5(1):194-203.
PMID: 39990948
PMC: 11843329.
DOI: 10.1021/acsbiomedchemau.4c00105.
Mohammed T, Zalzala M
J Exp Pharmacol. 2025; 17:93-105.
PMID: 39989470
PMC: 11844200.
DOI: 10.2147/JEP.S504511.
Yu T, Villalona P, Khan S, Mikeasky N, Meinert E, Magafas J
J Biol Chem. 2024; 301(2):108081.
PMID: 39675705
PMC: 11783427.
DOI: 10.1016/j.jbc.2024.108081.
Xu Y, Qian Y, Yu Y, Zhan X, Jin P, Hong J
Hepatology. 2024; 81(2):408-422.
PMID: 38986003
PMC: 11737122.
DOI: 10.1097/HEP.0000000000000994.
Farnesoid X receptor: From Structure to Function and Its Pharmacology in Liver Fibrosis.
Ding C, Wang Z, Dou X, Yang Q, Ning Y, Kao S
Aging Dis. 2023; 15(4):1508-1536.
PMID: 37815898
PMC: 11272191.
DOI: 10.14336/AD.2023.0830.
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A
Pharmacol Rev. 2023; 75(6):1233-1318.
PMID: 37586884
PMC: 10595025.
DOI: 10.1124/pharmrev.121.000436.
Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling.
Xie Y, Shen F, He Y, Guo C, Yang R, Cao H
Nutrients. 2023; 15(5).
PMID: 36904254
PMC: 10005659.
DOI: 10.3390/nu15051255.
Biomimetic Total Synthesis and the Biological Evaluation of Natural Product (-)-Fargesone A as a Novel FXR Agonist.
Guo F, Chen K, Dong H, Hu D, Gao Y, Liu C
JACS Au. 2023; 2(12):2830-2838.
PMID: 36590256
PMC: 9795464.
DOI: 10.1021/jacsau.2c00600.
The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.
Rausch M, Samodelov S, Visentin M, Kullak-Ublick G
Int J Mol Sci. 2022; 23(22).
PMID: 36430444
PMC: 9695947.
DOI: 10.3390/ijms232213967.
Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.
Katafuchi T, Makishima M
Int J Mol Sci. 2022; 23(11).
PMID: 35682726
PMC: 9181207.
DOI: 10.3390/ijms23116046.
Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism.
Zhou W, Anakk S
Mol Cell Endocrinol. 2022; 549:111616.
PMID: 35304191
PMC: 9245558.
DOI: 10.1016/j.mce.2022.111616.
FXR: structures, biology, and drug development for NASH and fibrosis diseases.
Tian S, Chen S, Pan C, Li Y
Acta Pharmacol Sin. 2022; 43(5):1120-1132.
PMID: 35217809
PMC: 9061771.
DOI: 10.1038/s41401-021-00849-4.
Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.
She J, Gu T, Pang X, Liu Y, Tang L, Zhou X
Front Pharmacol. 2022; 12:772435.
PMID: 35069197
PMC: 8766425.
DOI: 10.3389/fphar.2021.772435.
Studies on the Importance of the 7α-, and 12α- hydroxyl groups of N-Aryl-3α,7α,12α-trihydroxy-5β-cholan-24-amides on their Antigermination Activity Against a Hypervirulent Strain of Clostridioides (Clostridium) difficile.
Sharma S, Yip C, Simon M, Phan J, Abel-Santos E, Firestine S
Bioorg Med Chem. 2021; 52:116503.
PMID: 34837818
PMC: 9236192.
DOI: 10.1016/j.bmc.2021.116503.
Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders.
Appelman M, van der Veen S, van Mil S
Front Endocrinol (Lausanne). 2021; 12:729828.
PMID: 34646233
PMC: 8503269.
DOI: 10.3389/fendo.2021.729828.
Conformational Characterization of the Co-Activator Binding Site Revealed the Mechanism to Achieve the Bioactive State of FXR.
Kumari A, Mittal L, Srivastava M, Pathak D, Asthana S
Front Mol Biosci. 2021; 8:658312.
PMID: 34532338
PMC: 8439381.
DOI: 10.3389/fmolb.2021.658312.
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.
Carpenter J, Wu G, Wang Y, Cook E, Wang T, Sitkoff D
ACS Med Chem Lett. 2021; 12(9):1413-1420.
PMID: 34531950
PMC: 8436248.
DOI: 10.1021/acsmedchemlett.1c00198.
Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer.
Tang Q, Evans R
Essays Biochem. 2021; 65(6):1015-1024.
PMID: 34414429
PMC: 8628182.
DOI: 10.1042/EBC20210038.
Farnesoid X receptor (FXR): Structures and ligands.
Jiang L, Zhang H, Xiao D, Wei H, Chen Y
Comput Struct Biotechnol J. 2021; 19:2148-2159.
PMID: 33995909
PMC: 8091178.
DOI: 10.1016/j.csbj.2021.04.029.